These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24403448)

  • 21. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
    Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
    Gade TP; Hassen W; Santos E; Gunset G; Saudemont A; Gong MC; Brentjens R; Zhong XS; Stephan M; Stefanski J; Lyddane C; Osborne JR; Buchanan IM; Hall SJ; Heston WD; Rivière I; Larson SM; Koutcher JA; Sadelain M
    Cancer Res; 2005 Oct; 65(19):9080-8. PubMed ID: 16204083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
    Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
    Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
    J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.
    Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W
    Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
    Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation.
    Chiu D; Tavaré R; Haber L; Aina OH; Vazzana K; Ram P; Danton M; Finney J; Jalal S; Krueger P; Giurleo JT; Ma D; Smith E; Thurston G; Kirshner JR; Crawford A
    Cancer Immunol Res; 2020 May; 8(5):596-608. PubMed ID: 32184296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.
    Henry MD; Wen S; Silva MD; Chandra S; Milton M; Worland PJ
    Cancer Res; 2004 Nov; 64(21):7995-8001. PubMed ID: 15520207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
    Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
    Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
    Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
    Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
    Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.
    Zuccolotto G; Fracasso G; Merlo A; Montagner IM; Rondina M; Bobisse S; Figini M; Cingarlini S; Colombatti M; Zanovello P; Rosato A
    PLoS One; 2014; 9(10):e109427. PubMed ID: 25279468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study.
    Sui CG; Wu D; Meng FD; Yang MH; Jiang YH
    Genet Mol Res; 2015 Jun; 14(2):7208-17. PubMed ID: 26125931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
    Wolf P; Freudenberg N; Bühler P; Alt K; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U
    Prostate; 2010 Apr; 70(5):562-9. PubMed ID: 19938014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.
    Behe M; Alt K; Deininger F; Bühler P; Wetterauer U; Weber WA; Elsässer-Beile U; Wolf P
    In Vivo; 2011; 25(1):55-9. PubMed ID: 21282735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.